ACADIA Pharmaceuticals Inc. (ACAD) announced Thursday morning that it has appointed Steve Davis as President and Chief Executive Officer.
The company also announced that it has submitted a New Drug Application to the FDA for approval for NUPLAZID, a treatment for psychosis associated with Parkinson's disease.
ACADIA Pharmaceuticals has gapped open sharply higher this morning and is now up 3.93 at $42.00. The stock has jumped above a trading range and has set nearly a 1-month high.
For comments and feedback contact: editorial@rttnews.com
Business News